NY A09830

Expands the scope of diagnostic pharmaceuticals optometrists may use to include topical applications to the eye and adnexa, removing the previous restrictive list of specific drug categories.

Broadens topical therapeutic pharmaceutical agents authorization to allow all FDA-approved and commercially available topical agents for the eye and adnexa, eliminating the previous enumerated list of nine specific drug categories.

Removes the specific enumerated list of drugs for treating glaucoma and ocular hypertension, instead authorizing all FDA-approved and commercially available therapeutic agents for these conditions applied to the eye and adnexa.

Replaces terminology in certification requirements from "phase one" and "phase two drugs" with "topical therapeutic agents" and "therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension."

Takes effect immediately upon enactment.